Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 13, 2009 - Issue 5
Submit an article Journal homepage
284
Views
26
CrossRef citations to date
0
Altmetric
Reviews

Inhibition of HGF/MET as therapy for malignancy

Sanjay Naran University of Pittsburgh School of Medicine, Division of Surgical Oncology, Department of Surgery, Pittsburgh, PA 15261, USA
,
Xinglu Zhang University of Pittsburgh School of Medicine, Division of Surgical Oncology, Department of Surgery, Pittsburgh, PA 15261, USA
&
Steven J Hughes University of Pittsburgh School of Medicine, Division of Surgical Oncology, Department of Surgery, Pittsburgh, PA 15261, USA; Associate Professor of Surgery, 497 Scaife Hall, 3550 Terrace Street, Pittsburgh, PA 15261, USA +1 412 947 0132; +1 412 578 9487; [email protected]
, MD
Pages 569-581 | Published online: 27 Apr 2009

Bibliography

  • Lengyel E, Sawada K, Salgia R. Tyrosine kinase mutations in human cancer. Curr Mol Med 2007;7(1):77-84
  • Laird AD, Cherrington JM. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin Investig Drugs 2003;12(1):51-64
  • Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7(6):504-16
  • Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316(5827):1039-43
  • Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251(4995):802-4
  • Di Renzo MF, Narsimhan RP, Olivero M. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 1991;6:1997-2003
  • Tsarfaty I, Rong S, Resau JH, et al. The Met proto-oncogene mesenchymal to epithelial cell conversion. Science 1994;263(5143):98-101
  • Bladt F, Riethmacher D, Isenmann S, et al. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995;376(6543):768-71
  • Schmidt C, Bladt F, Goedecke S, et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995;373(6516):699-702
  • Chmielowiec J, Borowiak M, Morkel M, et al. c-Met is essential for wound healing in the skin. J Cell Biol 2007;177(1):151-62
  • Neuss S, Becher E, Wöltje M, et al. Functional expression of HGF and HGF receptor/c-met in adult human mesenchymal stem cells suggests a role in cell mobilization, tissue repair, and wound healing. Stem Cells 2004;22(3):405-14
  • Jiang W, Hiscox S, Matsumoto K, Nakamura T. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol 1999;29(3):209-48
  • Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4(12):915-25
  • Gao CF, Vande Woude GF. HGF/SF-Met signaling in tumor progression. Cell Res 2005;15(1):49-51
  • Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003;22(4):309-25
  • Ponzetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994;77(2):261-71
  • Nakanishi K, Fujimoto J, Ueki T, et al. Hepatocyte growth factor promotes migration of human hepatocellular carcinoma via phosphatidylinositol 3-kinase. Clin Exp Metastasis 1999;17(6):507-14
  • Maroun CR, Holgado-Madruga M, Royal I, et al. The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol 1999;19(3):1784-99
  • Weidner KM, Di Cesare S, Sachs M, et al. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 1996;384(6605):173-6
  • Gu H, Neel BG. The “Gab” in signal transduction. Trends Cell Biol 2003;13(3):122-30
  • Xiao GH, Jeffers M, Bellacosa A, et al. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci USA 2001;98(1):247-52
  • Boccaccio C, Andò M, Tamagnone L, et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 1998;391(6664):285-8
  • Furge KA, Zhang YW, Vande Woude GF. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene, 2000;19(49):5582-9
  • Maina F, Panté G, Helmbacher F, et al. Coupling Met to specific pathways results in distinct developmental outcomes. Mol Cell 2001;7(6):1293-306
  • Ridley AJ, Comoglio PM, Hall A. Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells. Mol Cell Biol 1995;15(2):1110-22
  • Gual P, Giordano S, Williams TA, et al. Sustained recruitment of phospholipase C-γ to Gab1 is required for HGF-induced branching tubulogenesis. Oncogene 2000;19(12):1509-18
  • Apte U, Zeng G, Muller P, et al. Activation of Wnt/β-catenin pathway during hepatocyte growth factor-induced hepatomegaly in mice. Hepatology 2006;44(4):992-1002
  • Monga SP, Mars WM, Pediaditakis P, et al. Hepatocyte growth factor induces Wnt-independent nuclear translocation of β-catenin after Met-β-catenin dissociation in hepatocytes. Cancer Res 2002;62(7):2064-71
  • Wang R, Ferrell LD, Faouzi S, et al. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol 2001;153(5):1023-34
  • Hepatocyte growth factor/scatter factor, Met and cancer references. Grand Rapids, MI: Van Andel Institute. Available from: www.vai.org/met/. [Last accessed 21 March 2009]
  • Park M, Dean M, Cooper CS, et al. Mechanism of met oncogene activation. Cell 1986;45(6):895-904
  • Marshall DD, Kornberg LJ. Overexpression of scatter factor and its receptor (c-met) in oral squamous cell carcinoma. Laryngoscope 1998;108(9):1413-7
  • Olivero M, Rizzo M, Madeddu R, et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 1996;74(12):1862-8
  • Beviglia L, Matsumoto K, Lin CS, et al. Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression. Int J Cancer 1997;74(3):301-9
  • Parr C, Watkins G, Mansel RE, Jiang WG. The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 2004;10(1 Pt 1):202-11
  • Jin L, Fuchs A, Schnitt SJ, et al. Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer 1997;79(4):749-60
  • Guirouilh J, Le Bail B, Boussarie L, et al. Expression of hepatocyte growth factor in human hepatocellular carcinoma. J Hepatol 2001;34(1):78-83
  • Herrera LJ, El-Hefnawy T, Queiroz de Oliveira PE, et al. The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma. Neoplasia 2005;7(1):75-84
  • Jucker M, Günther A, Gradl G, et al. The Met/hepatocyte growth factor receptor (HGFR) gene is overexpressed in some cases of human leukemia and lymphoma. Leuk Res 1994;18(1):7-16
  • Wu CW, Li AF, Chi CW, et al. Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma. Oncol Rep 1998;5(4):817-22
  • Otte JM, Schmitz F, Kiehne K, et al. Functional expression of HGF and its receptor in human colorectal cancer. Digestion 2000;61(4):237-46
  • Cheng HL, Liu HS, Lin YJ, et al. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br J Cancer 2005;92(10):1906-14
  • Cheng HL, Trink B, Tzai TS, et al. Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J Clin Oncol 2002;20(6):1544-50
  • Li B, Kanamaru H, Noriki S, et al. Differential expression of hepatocyte growth factor in papillary and nodular tumors of the bladder. Int J Urol 1998;5(5):436-40
  • Zhu X, Humphrey PA. Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma. Urology 2000;56(6):1071-4
  • Imaizumi Y, Murota H, Kanda S, et al. Expression of the c-Met proto-oncogene and its possible involvement in liver invasion in adult T-cell leukemia. Clin Cancer Res 2003;9(1):181-7
  • Hino M, Inaba M, Goto H, et al. Hepatocyte growth factor levels in bone marrow plasma of patients with leukaemia and its gene expression in leukaemic blast cells. Br J Cancer 1996;73(1):119-23
  • Seidel C, Børset M, Hjorth-Hansen H, et al. Role of hepatocyte growth factor and its receptor c-met in multiple myeloma. Med Oncol 1998;15(3):145-53
  • Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005;225(1):1-26
  • Follenzi A, Bakovic S, Gual P, et al. Cross-talk between the proto-oncogenes Met and Ron. Oncogene 2000;19(27):3041-9
  • Jo M, Stolz DB, Esplen JE, et al. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 2000;275(12):8806-11
  • Ma PC, Jagadeesh S, Jagadeeswaran R, et al. c-MET expression/activation, functions, and mutations in non-small cell lung cancer. Proc Am Assoc Cancer Res 2004;44:1875
  • Di Renzo MF, Olivero M, Martone T, et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000;19(12):1547-55
  • Ichimura E, Maeshima A, Nakajima T, Nakamura T. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 1996;87(10):1063-9
  • Knudsen BS, Vande Woude G. Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev 2008;18(1):87-96
  • Migliore C, Giordano S. Molecular cancer therapy: can our expectation be MET? Eur J Cancer 2008;44(5):641-51
  • Toschi L, Janne PA. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer. Clin Cancer Res 2008;14(19):5941-6
  • Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 2002;20(1):325-34
  • Bardelli A, Longati P, Williams TA, et al. A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth. J Biol Chem 1999;274(41):29274-81
  • Morotti A, Mila S, Accornero P, et al. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 2002;21(32):4885-93
  • Jagadeeswaran R, Jagadeeswaran S, Fackenthal J, et al. c-Met/HGF pathway in breast cancer cells and inhibition with specific small molecule inhibitor, SU11274. AACR Meeting Abstracts. 2005;2005(1):1229-a
  • Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005;65(4):1479-88
  • Blazek ER, Bonomi PD, Plate J. Simultaneous inhibition of EGFR and c-Met pathways in a panel of NSCLC cell lines [abstract 22223]. J Clin Oncol 2008;2008(26 Suppl)
  • Christensen JG, Schreck R, Burrows J, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003;63(21):7345-55
  • Smolen GA, Sordella R, Muir B, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 2006;103(7):2316-21
  • Jeay S, Munshi N, Hill J, et al. ARQ197, a highly selective small molecule inhibitor of c-Met, with selective antitumor properties in a broad spectrum of human cancer cells. AACR Meeting Abstracts 2007. [Abstract 2369]
  • Munshi N, Jeay S, Hill J, et al. ARQ197, a highly selective inhibitor of c-Met, inhibits invasive and metastatic growth of cancer cells. AACR Meeting Abstracts 2007. [Abstract 2367]
  • Li Y, Chen D, Zhou W, et al. Broad spectrum anti-cancer activity of ARQ197, a highly selective oral c-Met inhibitor, in multiple xenograft models. AACR Meeting Abstracts 2007. [Abstract 2216]
  • ArQule Inc. A Phase 2 study of ARQ 197 in patients with microphthalmia transcription factor associated tumors. Available from: http://clinicaltrials.gov/ct2/show/NCT00557609 [Last accessed 21 March 2009]
  • ArQule Inc. A Phase 1 dose escalation study of ARQ 197 Given twice daily continuously in adult patients with advanced solid tumors. Available from: http://clinicaltrials.gov/ct2/show/NCT00612209 [Last accessed 21 March 2009]
  • GlaxoSmithKline. A Phase 2 study of the MET RTK inhibitor GSK1363089 (Formerly XL880) in subjects with recurrent or metastatic squamous cell cancer of the head and neck. Available from: http://clinicaltrials.gov/ ct2/show/NCT00725764 [Last accessed 21 March 2009]
  • GlaxoSmithKline. A dose escalation study of the safety and pharmacokinetics of GSK1363089 (Formerly XL880) administered orally to subjects with solid tumors. Available from: http://clinicaltrials.gov/ct2/show/NCT00742131 [Last accessed 21 March 2009]
  • Ross R. Srinivasan R, Vaishampayan U, et al. A Phase 2 study of the dual MET/VEGFR2 inhibitor XL880 in patients with papillary renal carcinoma. AACR Meeting Abstracts. 2007;2007:B249
  • Srinivasan R, Choueiri TK, Vaishampayan U, et al. A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC) [abstract 5103]. J Clin Oncol 2008;26(20 Suppl)
  • Froning KJ. Felce J, Jessen K, et al. SGX-70329: a potent and highly selective small molecule inhibitor of the MET receptor tyrosine kinase. AACR Meeting Abstracts 2007 [Abstract 2366]
  • SGX Pharmaceuticals Inc. Discontinued Development of SGX523. Available from: http://www.biospace.com/news_story.aspx?NewsEntityId=96099 [Last accessed 21 March 2009]
  • Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007;6(12 Pt 1):3314-22
  • Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67(9):4408-17
  • Pfizer. Phase 1 Safety, A study of oral PF-02341066, a c-Met/hepatocyte growth factor tyrosine kinase inhibitor, in patients with advanced cancer. Available from: http://clinicaltrials.gov/ ct2/show/NCT00585195 [Last accessed 21 March 2009]
  • SuperGen. MP470 and chemotherapy in treating patients with cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00602875 [Last accessed 21 March 2009]
  • Parr C, Hiscox S, Nakamura T, et al. Nk4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells. Int J Cancer 2000;85(4):563-70
  • Matsumoto K, Nakamura T. NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci 2003;94(4):321-7
  • Matsumoto K, Nakamura T. NK4 gene therapy targeting HGF-Met and angiogenesis. Front Biosci 2008;13:1943-51
  • Chan AM, Rubin JS, Bottaro DP, et al. Identification of a competitive HGF antagonist encoded by an alternative transcript. Science 1991;254(5036):1382-5
  • Otsuka T, Jakubczak J, Vieira W, et al. Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis. Mol Cell Biol 2000;20(6):2055-65
  • Jun HT, Sun J, Rex K, et al. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res 2007;13(22 Pt 1):6735-42
  • Amgen. A Phase 1b/2 Trial of AMG 479 or AMG 102 in combination with platinum-based chemotherapy as first-line treatment for extensive stage small cell lung cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00791154 [Last accessed 21 March 2009]
  • Amgen. A Phase II Study to Treat Advanced Malignant Glioma. Available from: http://clinicaltrials.gov/ct2/show/NCT00427440 [Last accessed 21 March 2009]
  • Amgen. A Phase II study to treat subjects with advanced renal cell carcinoma. Available from: http://clinicaltrials.gov/ct2/show/NCT00422019 [Last accessed 21 March 2009]
  • Mazzone M, Basilico C, Cavassa S, et al. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest 2004;114(10):1418-32
  • Michieli P, Basilico C, Pennacchietti S, et al. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene 1999;18(37):5221-31
  • Michieli P, Mazzone M, Basilico C, et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004;6(1):61-73
  • Neckers L, Schulte TW, Mimnaugh E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest New Drugs 1999;17(4):361-73
  • Webb CP, Hose CD, Koochekpour S, et al. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-Met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res 2000;60(2):342-9
  • Abounader R, Ranganathan S, Lal B, et al. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J Natl Cancer Inst 1999;91(18):1548-56
  • Betsunoh H, Mukai S, Akiyama Y, et al. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. Cancer Sci 2007;98(4):491-8
  • Ayhan A, Ertunc D, Tok EC, Ayhan A. Expression of the c-Met in advanced epithelial ovarian cancer and its prognostic significance. Int J Gynecol Cancer 2005;15(4):618-23
  • Ide T, Kitajima Y, Miyoshi A, et al. The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling. Ann Surg Oncol 2007;14(9):2600-7
  • Rong S, Jeffers M, Resau JH, et al. Met expression and sarcoma tumorigenicity. Cancer Res 1993;53(22):5355-60
  • Fukuda T, Ichimura E, Shinozaki T, et al. Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. Pathol Int 1998;48(10):757-62
  • Rees H, Williamson D, Papanastasiou A, et al. The MET receptor tyrosine kinase contributes to invasive tumour growth in rhabdomyosarcomas. Growth Factors 2006;24(3):197-208
  • Koochekpour S, Jeffers M, Rulong S, et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 1997;57(23):5391-8
  • Li Y, Lal B, Kwon S, et al. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. Cancer Res 2005;65(20):9355-62
  • Gao L, Feng Y, Bowers R, et al. Ras-associated protein-1 regulates extracellular signal-regulated kinase activation and migration in melanoma cells: two processes important to melanoma tumorigenesis and metastasis. Cancer Res 2006;66(16):7880-8
  • Hecht M, Papoutsi M, Tran HD, et al. Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas. Cancer Res 2004;64(17):6109-18
  • Kim KJ, Wang L, Su YC, et al. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 2006;12(4):1292-8
  • Johnson & Johnson Pharmaceutical Research & Development, L.L.C. A safety and dose-finding study of JNJ-38877605 in patients with advanced or refractory solid tumors. Available from: http://clinicaltrials.gov/ct2/show/NCT00651365 [Last accessed 21 March 2009]
  • Martens T, Schmidt NO, Eckerich C, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006;12(20 Pt 1):6144-52

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.